ATC Group: A10BB Sulfonamides, urea derivatives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BB in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BB Sulfonamides, urea derivatives

Group A10BB contents

Code Title
A10BB01 Glibenclamide
A10BB02 Chlorpropamide
A10BB03 Tolbutamide
A10BB04 Glibornuride
A10BB05 Tolazamide
A10BB06 Carbutamide
A10BB07 Glipizide
A10BB08 Gliquidone
A10BB09 Gliclazide
A10BB10 Metahexamide
A10BB11 Glisoxepide
A10BB12 Glimepiride
A10BB31 Acetohexamide

Active ingredients in A10BB

Active Ingredient Description
Acetohexamide
Chlorpropamide

Chlorpropamide is a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. It appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which chlorpropamide lowers blood glucose during long-term administration has not been clearly established.

Glibenclamide

Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.

Glibornuride
Gliclazide

Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans.

Glimepiride

Glimepiride is an orally active hypoglycaemic substance belonging to the sulphonylurea group. It may be used in non-insulin dependent (type 2) diabetes mellitus. Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.

Glipizide

Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue.

Gliquidone

Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

Tolbutamide

Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin.

Related product monographs

Title Information Source Document Type  
AMARYL Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
AMGLIDIA Oral suspension European Medicines Agency (EU) MPI, EU: SmPC
DIABREZIDE Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
DIAMICRON MR Modified release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
GLIBESYN Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLICLAZIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
GLITISOL Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLIZOREM Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
GLUCOTROL Tablet FDA, National Drug Code (US) MPI, US: SPL/Old
GLUCOTROL XL Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
LAMZARIN Prolonged-release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
MEDOCLAZIDE Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
MINIDIAB Tablet Pharmaceutical Benefits Scheme (AU) MPI, EU: SmPC
MINODIAB Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC